Ligand Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Ligand Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Summary
Marketlines Ligand Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ligand Pharmaceuticals, Inc. since January2007.
Synopsis
Marketlines Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes Ligand Pharmaceuticals, Inc.s contact information and business Summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Ligand Pharmaceuticals, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on Ligand Pharmaceuticals, Inc.s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Ligand Pharmaceuticals, Inc. and its subsidiaries since 2007.
- Information about key financial and legal advisors for Ligand Pharmaceuticals, Inc.s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons to buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Ligand Pharmaceuticals, Inc.s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors business structure and growth strategies.
Summary
Marketlines Ligand Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ligand Pharmaceuticals, Inc. since January2007.
Synopsis
Marketlines Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes Ligand Pharmaceuticals, Inc.s contact information and business Summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Ligand Pharmaceuticals, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on Ligand Pharmaceuticals, Inc.s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Ligand Pharmaceuticals, Inc. and its subsidiaries since 2007.
- Information about key financial and legal advisors for Ligand Pharmaceuticals, Inc.s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons to buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Ligand Pharmaceuticals, Inc.s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors business structure and growth strategies.
TABLE OF CONTENTS
COMPANY OVERVIEW AND KEY FACTS
MERGERS & ACQUISITIONS
--Mergers and Acquisitions - Overview
--Mergers and Acquisitions - Deal reports
CORPORATE VENTURING
--Corporate Venturing - Overview
--Corporate Venturing - Deal reports
PARTNERSHIP
--Partnership - Overview
--Partnership - Deal reports
CAPITAL RAISING
--Capital Raising - Overview
--Capital Raising - Deal reports
--Divestments - Deal reports
APPENDIX
--About MarketLine Financial Deals Database
--Deal Definition and Methodology
--About MarketLine
--MarketLine Professional Services Knowledge Center
List Of Tables
--Ligand Pharmaceuticals activity by deal type - volume (2013 -YTD2017)
--Ligand Pharmaceuticals M&A average deal size - value ($m) (2013 -YTD2017)
--Ligand Pharmaceuticals legal advisor ranking by value ($m)
--Ligand Pharmaceuticals financial advisor ranking by value ($m)
--Top Deals(2013 -YTD2017)
--Ligand Pharmaceuticals targets and partners (2013 -YTD2017)
--Ligand Pharmaceuticals M&A volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals M&A activity by geography (2013-YTD2017)
--Ligand Pharmaceuticals corporate venturing volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals corporate venturing by geography (2013-YTD2017)
--Ligand Pharmaceuticals partnership volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals partnership trend by key deal type (2013-YTD2017)
--Ligand Pharmaceuticals capital raising volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals capital raising by deal type (2013-YTD2017)
List Of Figures
--Ligand Pharmaceuticals activity by deal type - volume (2013-YTD2017)
--Ligand Pharmaceuticals M&A average deal size - value ($m)
--Ligand Pharmaceuticals M&A volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals M&A activity by geography (2013-YTD2017)
--Ligand Pharmaceuticals corporate venturing volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals corporate venturing by geography (2013-YTD2017)
--Ligand Pharmaceuticals partnership volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals partnership trend by key deal type (2013-YTD2017)
--Ligand Pharmaceuticals capital raising volume and value trend (2013-YTD2017)
--Ligand Pharmaceuticals capital raising by deal type (2013-YTD2017)
RELATED REPORTS
Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) - Drugs in Development, 2021
Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) - Drugs in Development, 2021Tumor Necrosis Factor (Cachectin or TNF
View ReportCells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021
Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1
View ReportRecursion Pharmaceuticals, Inc. - Tech Innovator Profile
Recursion Pharmaceuticals, Inc. - Tech Innovator ProfileRecursion Pharmaceuticals, Inc. is a biotechnology company. Recursion combines experimental biology and bioinformatics with artificial intelligence (AI) in a parallel system to identify treatments
View ReportAntiglaucoma Drugs Global Market Report 2020 Including: 1) By Product Type: Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, Others 2) By Disease Condition Type: Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma 3) By Type: Hospital Prescription drugs, Over-the counter drugs Covering: Aerie Pharmaceuticals, Inc., ALLERGAN, Novartis AG, Abbott Healthcare, Johnson & Johnson
Antiglaucoma Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global antiglaucoma drugs market.Reasons
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
